BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW
bioAffinity Technologies, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.51−0.22 (-5.90%)
Close on Oct 19, 2026
- Market cap
- $18.35M
- P/E (TTM)
- –
- Dividend yield
- –
bioAffinity Technologies statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Commercial Physical & Biological Research companies for comparison
Valuation
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Market Cap | $28.44M | $73.61M |
| Enterprise Value | $26.04M | $54.02M |
| PS Ratio | 4.82 | 3.27 |
| PB Ratio | 7.55 | 2.99 |
| P/TBV Ratio | 16.96 | 7.11 |
Enterprise value
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| EV / Sales | 4.41 | 2.80 |
Income (trailing twelve months)
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Revenue | $5.90M | $23.60M |
| Operating Income | -$12.38M | -$55.64K |
| Pretax Income | -$15.18M | $45.62K |
| Net Income | -$15.19M | -$80.05K |
| EBITDA | -$11.97M | -$29.48K |
Margins
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Operating Margin | -209.8% | 0.88% |
| Pretax Margin | -257.2% | 2.45% |
| Profit Margin | -257.3% | 0.51% |
| EBITDA Margin | -202.8% | 3.34% |
| FCF Margin | -195.9% | 5.05% |
Returns
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Return on Equity (ROE) | -1860.2% | 1.35% |
| Return on Assets (ROA) | -245.5% | -3.16% |
| Return on Capital Employed (ROCE) | -250.7% | 2.03% |
Growth
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -23.2% | 4.74% |
| Revenue Growth (3Y CAGR) | -3.70% | 4.21% |
Balance sheet
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.43M | $5.43M |
| Total Debt | $36.47K | $90.03M |
| Net Cash (Debt) | $2.39M | $17.62K |
| Net Cash Per Share | $0.30 | $0.00 |
| Equity (Book Value) | $3.77M | $11.51M |
| Book Value Per Share | $0.47 | $0.64 |
| Tangible Book Value | $1.68M | -$78.36K |
| Working Capital | $1.18M | $2.82M |
Financial position
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Current Ratio | 1.44 | 1.30 |
| Quick Ratio | 0.91 | 0.66 |
| Debt / Equity | 0.01 | 0.46 |
| Interest Coverage | -276.15 | -0.23 |
Cash flow (trailing twelve months)
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Operating Cash Flow | -$11.47M | $8.04K |
| Capital Expenditures | -$91.99K | -$8.33M |
| Free Cash Flow | -$11.56M | $11.03M |
| FCF Per Share | -$1.43 | $0.76 |
Efficiency
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Asset Turnover | 0.95 | 0.81 |
| Revenue Per Employee | $103.53K | $215.67K |
| Profits Per Employee | -$266.41K | -$799 |
| Employee Count | 57 | 115 |
Dividends and yields
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Earnings Yield | -53.4% | -0.97% |
| FCF Yield | -40.7% | 3.90% |
Shares
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Shares Outstanding | 8,101,730 | 29,217,800 |
| Shares Change (QoQ) | 50.8% | 0.00% |
| Float | 3,300,900 | 26,226,050 |
| Shares Held by Insiders | 59.3% | 4.85% |
| Shares Held by Institutions | 1.60% | 83.3% |
Scores
| Measure | bioAffinity Technologies | Industry median |
|---|---|---|
| Altman Z-Score | -13.85 | 2.64 |
| Piotroski F-Score | 2 | 5 |
Calculated by StockData from bioAffinity Technologies's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.